Evaluation of Safety and Efficacy of the Bifurcated Multilayer Flow Modulator (BMFM®).

Inclusion Criteria: Patients must meet ALL of the following criteria: * Age over 18 * Life expectancy \> 12 months * Aortic aneurysms involving iliac arteries * Healthy proximal and distal landing zone * Adequate arterial access * Healthy branches and collaterals (no stenosis or previously treated by angioplasty) * Informed consent understood, signed and patient agrees to all follow-up visits Exclusion Criteria: Patients will be excluded if ANY of the following conditions apply: * Aneurysm rupture, impending or contained rupture * Aortic dissection * Aortic root aneurysm * Pleural effusion * Prior all surgical procedure within 30 days unless procedure is in preparation for device implantation or planned within 30 days post stent deployment * Myocardial infarction or cerebral vascular accident within 6 weeks of treatment * Presence/suspicion of connective tissue disorders, for example, Marfan or Ehlers-Danlos etc. * Contraindications to the anticoagulant or/ and antiplatelet medications * Allergic reaction to a contrast agent * Patient with undergoing or planned chemotherapy * History of bleeding disorder (coagulopathy) or thrombophilia * Shaggy aorta * Takayasu's arteritis * Presence/suspicion of infection (for example: mycotic aorta) * The use of the MFM® with stent-grafts or previously implanted stent-grafts * Pregnant or breastfeeding woman * Patients included in another clinical study